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Abstract
Objective: Calcitonin gene-related peptide (CGRP) is a vasoactive, proinflammatory neuropeptide implicated
in the pathogenesis of cardiovascular disease. Elevated CGRP levels during hot flushes and pregnancy suggest
that reproductive hormones may influence CGRP secretion. CGRP and the related protein adrenomedullin (ADM)
may function through adipose tissueYmediated effects, since adipose tissue is an important site of cytokine
production and the main site for estrogen production after menopause. This study examined mRNA and protein
expression of CGRP, ADM, and the receptor activity-modifying proteins and the effects of menopausal status in
human adipose tissue.
Design: Protein/mRNA levels were determined in adipose tissue biopsy samples collected from premeno-
pausal (n = 22: follicle-stimulating hormone, G20 IU/L; estradiol [mean T SE], 434.5 T 87.81 pmol/L) and
postmenopausal (n = 25: follicle-stimulating hormone, 920 IU/L; estradiol, 43.4 T 6.95 pmol/L) women.
Results: Our studies determined that CGRP, ADM, and receptor activity-modifying proteins were expressed in
abdominal fat, adipocytes, and preadipocytes. CGRP and ADM mRNA levels were increased in abdominal
subcutaneous fat in postmenopausal women compared with premenopausal women (ACGRP: premenopause $
cycle threshold [Ct], 31.07 T 0.28 vs postmenopause $Ct, 30.35 T 0.17, P = 0.035; ADM: premenopause ScAQ1 $Ct,
12.41 T 0.2 vs postmenopause Sc $Ct, 11.55 T 0.14, P G 0.001) with CGRP differentially expressed in
subcutaneous and omental depots. CGRP protein expression was higher in postmenopausal women (P G 0.05) in
both fat depots.
Conclusions: Our findings suggest that adipose tissue represents an important site for CGRP and ADM
production and that menopause status alters their expression in abdominal fat. This offers a potential mechanism
to explain the role of CGRP in menopausal vasomotor symptoms and the increased risk of cardiovascular disease
in postmenopausal women.
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Adipose tissue.
T
he menopausal transition in women is associated with
weight gain, increased visceral fat content, and central
adiposity.1 Although recent studies have shown higher
body mass index (BMI) to be associated with increased
severity of hot flushes in postmenopausal women,2<7 the
mechanisms through which adipose tissue (AT) influences the
severity of these symptoms is not yet known. Calcitonin gene-
related peptide (CGRP), a vasoactive peptide, may have a role
in the onset of hot flushes. Elevated CGRP serum levels have
been observed during hot flushes in postmenopausal women
and in men after castration,8<10 linking acute release of CGRP
with the onset of vasomotor symptoms. Animal and human
studies have demonstrated that secretion and activity of
CGRP and adrenomedullin (ADM) are influenced by the sex
hormones. Increased plasma levels of CGRP have been noted
during pregnancy, although its hypotensive effects were
potentiated in the presence of the sex hormones.11,12 In
postmenopausal women, hormone therapy (HT) was associ-
ated with increased plasma CGRP levels.13 Similarly, circu-
latory ADM levels are influenced by the phase of menstrual
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cycle, and plasma levels are increased during normal
pregnancy.14,15
CGRP is a 37-amino-acid neuropeptide that exists in two
forms, > and beta A, that differ by three amino acids in
humans.16 It is widely distributed throughout the body, with
>CGRP being the predominant form in the central and
peripheral nervous system, although ACGRP is present in
the enteric system and pituitary gland.17 However, the
importance of their differential distribution and regulation
in vivo is not yet clear. Both isoforms have potent
vasodilatory capacity, although studies have suggested they
may have different signaling and regulatory mechanisms at
the receptor level.18,19
ADM, a 52-amino-acid peptide, is another member of the
calcitonin family and is produced by a variety of cells,
including vascular endothelial and smooth muscle cells.20
Although ADM is mainly active at the microvasculature
level, it is also present in the circulation in considerable
amounts.21,22 CGRP is secreted in the tissues by sensory
nerves and rapidly metabolized by tissue endopeptidases;
therefore, the small amount detectable in the circulation is
thought to be a spillover from the perivascular sensory nerve
endings.23,24 These studies suggest that local paracrine
effects may be more important than its systemic influence.
Both CGRP and ADM bind to a common receptor molecule
called calcitonin receptorYlike receptor (CRLR); however,
for the receptor to be functional, an additional transmem-
brane protein called receptor activity-modifying protein
(RAMP) is required. Three RAMPs (RAMP1, RAMP2,
RAMP3) determine the specificity of the receptor to either
CGRP or ADM because in the presence of RAMP1, the
CRLR acts primarily as a CGRP receptor, whereas in the
presence of RAMP2 and RAMP3, it acts as an ADM
receptor (ADM1 and ADM2). Alteration in RAMP expres-
sion provides another potential mechanism through which
cells may change their responsiveness to CGRP and ADM.25
We hypothesized that the local activity of AT-derived
CGRP may influence the severity of hot flushes by
regulating cutaneous vasodilatation. Therefore, the aim of
the study was to determine whether CGRP was expressed in
human AT and whether its expression was altered by
menopausal status. Because many AT-derived cytokines
are depot specific, we examined the expression of CGRP in
paired samples of subcutaneous (Sc) and omental (Om) AT.
In addition, we explored the possibility that expression of
ADM and the RAMPs in human AT may be influenced by
menopause status.
METHODS
Participants
For these studies, fasting blood samples (n = 31:
premenopausal, 22; postmenopausal, 9) and paired Sc and
Om AT samples were obtained from premenopausal and
postmenopausal women (n = 30: premenopausal, 22; post-
menopausal, 8) undergoing elective abdominal surgery for
benign conditions. Additionally, 17 unpaired abdominal Sc
(AbSc) AT samples were also collected from postmenopausal
women. Postmenopausal status was defined as amenorrhea for
more than 12 months along with serum follicle-stimulating
hormone (FSH) levels greater than 20 IU/L. In total, 77 ex vivo
AT samples were analyzed, comprising premenopausal AbSc
(n = 22), premenopausal abdominal Om (AbOm) (n = 22),
postmenopausal AbSc (n = 25), and postmenopausal AbOm
(n = 8). Women with any medical condition (ie, hypertension,
cardiovascular disease, thyroid disorders, renal disorders,
diabetes, or chronic pain conditions) were excluded from the
study. None of the women were on endocrine therapy (ie, HT,
tamoxifen, steroids, or antiglycemic agents) or any medication
that might have influenced CGRP secretion. All samples were
collected in accordance with the research protocol approved
by the Solihull Local Research Ethics Committee.
Collection of clinical data
Anthropometric data were collected to calculate BMI and
waist-hip ratio. Systolic and diastolic blood pressures were
recorded before sample collection. The date of last menstrual
period, cycle length, and regularity were recorded to determine
the menopause status in postmenopausal women (last men-
strual period 1-36 y) and phase of menstrual cycle in
premenopausal women. Women who were within the last 2
weeks of their cycle were classified as being in the luteal phase
(n = 11), and women who were in the earlier part of their cycle
were classified as being in the follicular phase (n = 6).
Collection, storage and analysis of samples
Fasting blood samples (minimum 6 h) were collected and
analyzed for serum glucose, insulin, estradiol, and FSH.
After collection, the serum and AT samples were immedi-
ately stored at j80-C until they were required for analysis.
Estradiol, FSH, and luteinizing hormone levels were deter-
mined using electrochemiluminescence immunoassays
(Roche Diagnostics) (estradiol reference range, 18.4-15,781
pmol/L; coefficient of variation [CV]: intrabatch, 5.7%;
interbatch, 6.2%; FSH reference range, 0.1-200 IU/L; CV
intrabatch, 2.8%; interbatch, 4.5%; luteinizing hormone
reference range, 0.1-200 mIU/mL; CV intrabatch, 1.8%;
interbatch, 5.2%). The samples for serum glucose were
collected into fluoride oxalate tubes and analyzed using an
automated colorimetric method (Roche Diagnostics) (refer-
ence range, 3.89-6.38 mmol/L; CV intrabatch, 0.9%;
interbatch, 1.8%). Serum insulin levels were determined
using a solid-phase enzyme amplified sensitivity immuno-
assay (Linco Research Inc) (reference range, 2-200 KU/mL;
CV intra-assay, 5.96%; interassay, 10.3%). HOMA AQ2scores
were calculated as fasting glucose (mmol/L)  fasting
insulin (KIU/mL)/22.5.
Isolation and culture of mature adipocytes
and preadipocytes
In brief, 10 to 20 g (wet weight) of fresh AT was collected.
Tissue was initially washed with 1 Hanks’ balanced salt
solution containing penicillin (100 U/mL) and streptomycin
(100 Kg/mL). Visible blood vessels and connective tissue
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were removed, and the tissue was finely chopped. All AT was
digested with the same batch of collagenase class 1 (2 mg/mL,
Worthington Biochemical Corp) in 1 Hanks’ balanced salt
solution (Gibco, Paisley, UK) for 20 minutes at 37-C.26 The
disrupted tissue was filtered through a double-layered cotton
mesh, and preadipocytes and adipocytes were separated by
centrifugation at 360g for 5 minutes. The upper layer of
mature adipocytes was then removed from the collagenase-
dispersed preparation, washed in phenol red-free medium
Dulbecco modified Eagle medium (DMEM:F12) twice, and
centrifuged at 360g for 2 minutes. The isolated adipocytes
(1 mL, consisting of approximately 500,000 mature adipo-
cytes) were maintained in flasks (25 cm2) of DMEM:F12
containing 15 mmol/L glucose, penicillin (100 U/mL) and
streptomycin (100 Kg/mL) for 48 hours.
Protein extraction and quantification from adipose
tissue and adipocytes
Proteins were extracted from whole AT using the Cam-
bridge radioimmunoprecipitation assay protein extraction
method.27 AT (100 mg) was resuspended in 300 KL
radioimmunoprecipitation assay buffer and homogenized
for 30 seconds (Fisher Scientific). The resulting mixture
was then flash frozen, allowed to thaw at room temperature,
and subsequently spun at 13,000 rpm for 30 minutes at 4-C.
Infranatant was collected and stored at j80-C. The method-
ology for protein extraction from adipocytes and preadipo-
cytes was identical to AT except that 500 KL of the cell
sample was mixed with 200 KL of radioimmunoprecipitation
assay buffer before flash freezing and spinning. After
extraction, protein concentrations were determined using
the Bio-Rad detergent-compatible protein assay kit.28
RNA extraction from adipose tissue, adipocytes,
and preadipocytes
Total RNA was isolated from whole AT, adipocytes, and
preadipocytes using a column-based method, according to the
manufacturer’s instructions (RNeasy Lipid Tissue Mini Kit,
Qiagen). After RNA extraction, a DNA digestion step was
performed (DNase Kit, Sigma) to remove any contaminating
genomic DNA. RNA from adipocytes and preadipocytes was
also extracted in a similar manner. RNA (1 Kg) from each
sample was reverse-transcribed using RevertAid H minus
M-MuLV reverse-transcriptase (Fermentas) and random
hexamers, in accordance with the manufacturer’s instructions.
Real-time polymerase chain reaction
The reverse transcriptaseYpolymerase chain reaction (RT-
PCR) was performed on the 7700 sequence detection system
in 25 KL volumes on 96-well plates in a reaction buffer
containing Taqman universal PCR master mix (containing
1.25 U AmpliTaq Gold DNA polymerase, 1.25 U AmpErase
UNG, 200 Kmol deoxyribonucleoside triphosphate with
deoxyuridine triphosphate passive reference and optimized
buffer component), 100 to 200 nmol Taqman probe, 900
nmol primers, and 15 to 30 ng cDNA. Previously detailed
primer and probe sequences for the CD45 gene were used to
analyze CD45 mRNA expression.27 Previous studies have
highlighted CGRP mRNA expression in macrophages.29,30
Therefore, we assessed AT depots and isolated adipocytes,
examining the impact of CGRP expression attributable to
macrophages by using CD45 as a marker for macrophages.
Quantitative primer and probe sequences for CD45 were
forward primer 5¶ CGT AAT GGA AGT GCT GCA ATG T 3¶,
reverse primer 5¶ CTG GGA GGC CTA CAC TTG ACA 3¶,
and Taqman probe 5¶ ACA ACT AAA AGT GCT CCT CCA
AGC CAG GTC T 3¶ (accession number NM_080922).27 The
mRNA levels for >CGRP, ACGRP, ADM, RAMP1, RAMP2,
and RAMP3 were analyzed using ABI predesigned gene
expression assay-on-demand kits (Applera, Warrington, UK).
All reactions were multiplexed with the housekeeping gene
18S, provided as a preoptimized control probe (Applera),
enabling data to be expressed in relation to an internal
reference to allow for differences in reverse-transcription
efficiency.
Reactions were as follows: 50-C for 2 minutes and 95-C
for 10 minutes, and then 44 cycles at 95-C for 15 seconds
and 16-C for 1 minute. The data were obtained as cycle
threshold (Ct) values according to the manufacturer’s
guidelines (the cycle number at which the logarithmic PCR
plot crosses a calculated threshold line) and used to
determine $Ct values ($Ct = Ct of the gene of interest
FIG. 1. The mean relative fold difference in mRNA expression of
>CGRP (A) and ACGRP (B) in premenopausal omental (Pre Om),
postmenopausal subcutaneous (Post Sc), and postmenopausal omental
(Post Om) adipose tissue depots relative to the premenopausal
subcutaneous (Pre Sc) adipose depot. The 18S gene has been used as
a preoptimized control probe (Applera, Warrington, UK). CGRP,
calcitonin gene-related peptide; Ct, cycle threshold.
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minus Ct of the 18S gene). A lower $Ct value means the
earlier appearance of the gene and thus higher expression of
the gene. All measurements were carried out in triplicate for
each sample. The individual $Ct values were averaged for
all samples for comparisons among participants and the
depots of the same participants. Similarly, the $Ct values for
each group of AT biopsy samples (premenopausal Sc,
premenopausal Om, postmenopausal Sc, postmenopausal
Om) were averaged to calculate a group mean, SD, and
SEM for each depot. Independent t tests were used to
analyze the group means for each depot. The relative fold
difference (as shown inF1-F4 Figs. 1<4) for all the mRNA
expression was calculated using the premenopausal AbSc
group as a reference, which was given an arbitrary value of
1. All the data were statistically analyzed at the $Ct stage to
avoid potential bias of averaging data that had been trans-
formedAQ3 through the equation 2-$$Ct.
Western blot
For Western blot analysis, 20 Kg of AT protein samples
were loaded onto a 15% polyacrylamide gel. After gel electro-
phoresis and electroblotting, the membrane was incubated
with a primary monoclonal mouse antibody for human CGRP
(Biohit Diagnostics, Devon, UK). Detection of CGRP was
achieved using a horseradish peroxidase-conjugated secondary
antibody (Binding Site, Birmingham, UK) diluted 1:80,000
in phosphate-buffered saline-T (0.05%T). A chemiluminescent
detection system (ECL Advanced, Amersham Pharmacia
Biotech, Little Chalfont, UK) was used to visualize bands after
x-ray exposure. In addition, 40Kg of mature adipocytes and 40
Kg of preadipocytes were used to assess CGRP protein
expression. Autoradiographs were quantified by densitome-
try using a Gelbase/Gelblot program (UVP Ltd).
FIG. 2. The standardized mean expression of CGRP protein (T SEM)
in human subcutaneous (Sc) and omental (Om) adipose tissue depots of
premenopausal (Pre) and postmenopausal (Post) adipose tissue depots,
by Western blot. Autoradiographs quantified by densitometry using a
Gelbase/Gelblot program (UVP Ltd). Statistical analysis compared
expression of CGRP in premenopausal depots versus postmenopausal
depots. Representative Western blots for CGRP and the precursor
protein are shown at top. The > tubulin Western blot (uppermost)
demonstrates equal loading of the protein. CGRP, calcitonin gene-
related peptide.
FIG. 3. The relative fold difference in mRNA expression of adreno-
medullin (ADM) in premenopausal omental (Pre Om), postmenopausal
subcutaneous (Post Sc), and postmenopausal omental (Post Om)
adipose tissue depots relative to the premenopausal subcutaneous (Pre
Sc) adipose depot. The 18S gene has been used as a preoptimized
control probe (Applera, Warrington, UK). Ct, cycle threshold.
FIG. 4. The relative fold difference in mRNA expression of RAMP1
(A), 2 (B), and 3 (C) in premenopausal omental (Pre Om),
postmenopausal subcutaneous (Post Sc), and postmenopausal omental
(Post Om) adipose tissue depots relative to the premenopausal
subcutaneous (Pre Sc) adipose depot. The 18S gene has been used as
a preoptimized control probe (Applera, Warrington, UK). RAMP,
receptor activity-modifying protein; Ct, cycle threshold.
AQ4
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Statistical analysis
Statistical analysis was performed using SPSS statistical
software (version 12). Paired and unpaired Student t tests
were used to analyze the expression of mRNA and proteins.
Correlations for continuous variables affecting CGRP,
ADM, and RAMP mRNA expression were determined by
calculating Pearson correlation coefficients. The significance
threshold was taken as P G 0.05. The data are presented as
mean T SEM unless stated otherwise.
RESULTS
Baseline characteristics
As expected, the postmenopausal women were older
(mean age: pre, 43.3 T 1.51 y; post, 59.8 T 1.77 y), had
lower mean serum estradiol levels (pre, 434.5 T 87.81 pmol/L;
post, 43.3 T 6.95 pmol/L), and higher mean serum FSH levels
(pre, 9.1 T 2.67 IU/L; post, 63.6 T 9.72 IU/L). Mean systolic
blood pressure was higher in the postmenopausal group (P =
0.015); however, the two groups were comparable in mean
diastolic blood pressure, BMI, waist circumference, waist-
hip ratio, serum glucose, and insulin levels (T1 Table 1).
CGRP mRNA expression in adipose tissue, mature
adipocytes, and preadipocytes
Both >CGRP and ACGRP mRNA were expressed in
AbSc and Om AT depots. The >CGRP expression was
similar in Sc and Om AT, but the expression was
significantly lower in the Om depot from postmenopausal
women compared with that from the premenopausal women
(mean T SEM $Ct: premenopausal Sc, 29.45 T 0.6;
premenopausal Om, 29.06 T 0.44; postmenopausal Sc, 30.1 T
0.26; postmenopausal Om, 30.11 T 0.26) (Fig. 1A). The
ACGRP showed higher expression in both Sc and Om adipose
depots from the postmenopausal women than from
the premenopausal women (mean T SEM $Ct: premeno-
pausal Sc, 31.07 T 0.28; premenopausal Om, 30.63 T 0.24;
postmenopausal Sc, 30.35 T 0.17; postmenopausal Om,
30.15 T 0.36) (Fig. 1B). CGRP mRNA was also found to
be expressed by mature adipocytes (n = 6) and preadipocytes
(n = 9). However, this was not attributed to macrophage
contamination, as CD45, the macrophage marker, remained
undetected in preadipocytes and mature adipocytes.
CGRP protein expression in adipose tissue, mature
adipocytes, and preadipocytes
Western blotting showed that CGRP was expressed in all
AT depots (Fig. 2) as well as mature adipocytes and
preadipocytes (data not shown). Sc and Om AT depots from
the postmenopausal women showed higher expression of
CGRP protein compared with the premenopausal women
(P G 0.05), although no difference in CGRP protein
expression was observed between Sc and Om depots (Fig. 2).
Expression of ADM mRNA in adipose tissue
and mature adipocytes
ADM was highly expressed in all the AT depots (mean T
SEM $Ct: premenopausal Sc, 12.41 T 0.2; premenopausal
Om, 12.11 T 0.24; postmenopausal Sc, 11.55 T 0.14; post-
menopausal Om, 12.53 T 0.36). The postmenopausal Sc
adipose depot showed a 1.8-fold increase in ADM expres-
sion compared with the premenopausal Sc tissue (P G 0.001;
Fig. 3). The ADM was also expressed in isolated adipocytes
(data not shown).
Expression of RAMPs (1, 2, 3) mRNA in adipose
tissue and mature adipocytes
All three RAMPs were expressed in Sc and Om AT, with
RAMP2 showing the highest expression overall. RAMP
expression was not influenced by menopause status as no
differential expression was observed (Fig. 4A-C). Only
RAMP1 showed depot-specific gene expression, with the
Om depots showing increased mRNA expression (pre Sc/pre
Om, 1:6.6; pre Sc/post Om, 1:18). The RAMPs were also
expressed in isolated adipocytes, with RAMP2 again show-
ing greatest mRNA expression (mean T SEM $Ct: RAMP1,
22.66 T 0.94; RAMP2, 17.07 T 0.87; RAMP3, 29.08 T 1.55).
Effects of menstrual phase on CGRP, ADM,
and RAMP mRNA expression
Among premenopausal women, the expression of >CGRP
mRNA was higher in women in follicular phase of the
menstrual cycle compared with those in the luteal phase
(mean T SEM $Ct: follicular, 28.11 T 0.54; luteal, 30.42 T
0.60, P = 0.01). No effect of menstrual phase was observed on
mRNA expression of ACGRP, ADM, or any of the RAMPs.
Effects of covariates on CGRP, ADM,
and RAMP mRNA expression
ADM mRNA expression and ACGRP mRNA were
positively correlated with age (ACGRP: r = j0.25, P =
0.028; ADM: r = j0.279, P = 0.014), suggesting a higher
expression of these mRNA in older women. >CGRP mRNA
expression, however, did not show such a correlation,
suggesting no influence of age on the expression of >CGRP
mRNA. ADM and >CGRP were positively correlated with
each other (r = 0.394, P = 0.001); however, there was no
correlation of ADM and >CGRP with any of the RAMPs.
ACGRP mRNA expression was positively correlated with
RAMP2 (r = 0.586, P G 0.001) and RAMP1 when controlled
for age (r = 0.555, P = 0.001), the two RAMPs necessary for
binding of ACGRP to the receptor indicating a simultaneous
TABLE 1. Population characteristics of premenopausal and
postmenopausal groups
Premenopausal
(n = 22)
Postmenopausal
(n = 25) P
Age, y 43.32 (1.51) 59.80 (1.76) G0.001
BMI, kg/m2 27.43 (1.03) 27.25 (0.79) 0.89
Waist circumference, cm 87.43 (2.47) 87.47 (3.03) 0.99
Waist-hip ratio 0.83 (0.01) 0.81 (0.02) 0.30
Mean systolic BP, mm Hg 125.33 (3.52) 145.56 (8.69) 0.05
Mean diastolic BP, mm Hg 75.05 (1.95) 83.00 (5.16) 0.086
Serum glucose, mmol/L 5.14 (0.20) 5.12 (0.21) 0.97
Serum insulin, KU/mL 7.05 (1.34) 11.35 (3.65) 0.18
Values are mean (SEM). BP, blood pressure.
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up-regulation of their mRNA expression. RAMP2 expres-
sion was positively correlated with RAMP3 mRNA levels
(r = 0.346, P = 0.002). Furthermore, RAMP3 showed lower
mRNA expression in women with increasing waist-hip ratio,
ie, central adiposity (r = 0.33, P = 0.009) (F5 Fig. 5A-F).
DISCUSSION
CGRP is widely recognized as a neuropeptide released
from sensory nerves in the central and peripheral nervous
systems. The present study demonstrates that CGRP is
actively expressed at the mRNA and protein level in human
AT as well as in isolated mature adipocytes. In addition,
these studies have explored the potential mechanism of
CGRP action through ADM and RAMPs by examining
whether alteration in menopausal status affects receptor
expression, which may influence the role of CGRP as a
vasodilator. Our findings have established that AT and, more
specifically, isolated adipocytes act as a source of CGRP and
ADM. Furthermore, AbSc AT taken from postmenopausal
women has increased CGRP and ADM protein expression as
compared with that from premenopausal women.
Because of the homogeneity of >CGRP and ACGRP, it
was not possible to discriminate between the two isoforms at
the protein level. However, our mRNA findings suggest that
the higher level of CGRP protein in the AT from
postmenopausal women may arise from increased expression
of ACGRP, as the expression of >CGRP mRNA was much
lower in postmenopausal women compared with ACGRP.
This is consistent with previous findings, which have
highlighted ACGRP as the prevalent form in the enteric
system.17 Studies have also suggested that >CGRP and
ACGRP bind differently to the receptors and may have
different responses to their antagonists. Whereas >CGRP
mainly binds to the CGRP1 receptor, formed by the
association of CRLR with RAMP1, ACGRP may also bind
to the ADM receptor (ADM2) formed by the association of
CRLR and RAMP3.31 The linear correlation between
ACGRP mRNA and RAMPs 1, 2, and 3 observed in our
study indicates that, in AT, ACGRP may potentially be
acting through the ADM receptors in addition to CGRP. The
importance of this finding in vivo is not yet known.
CGRP is one of the many neuropeptides that have been
studied to understand the complex pathogenesis of meno-
pausal hot flushes. It is known that both neurogenic and
humoral mechanisms are involved in the altered cutaneous
thermoregulation, which is controlled by both the sympa-
thetic and sensory nervous systems via release of peptides
such as norepinephrine, neuropeptide Y, CGRP, and neuro-
kinin A.32,33 AT is a peripheral vascularized site that, by
regulating the production of CGRP, may participate in regu-
lating the cutaneous blood flow. Studies in rats have shown
that neuropeptides derived from the sympathetic nerves
located in white AT may influence lipid mobilization.34
FIG. 5. Bivariate correlations between mRNA expression (expressed as $Ct values) of ACGRP with age (A), adrenomedullin (ADM) with age (B),
ADM with >CGRP (C), RAMP3 with waist-hip ratio (D), ACGRP with RAMP2 (E), and ACGRP with RAMP3 (F). CGRP, calcitonin gene-related
peptide; Ct, cycle threshold; RAMP, receptor activity-modifying protein.
6 Menopause, Vol. 14, No. 6, 2007 * 2007 The North American Menopause Society
GUPTA ET AL
Copyright @ 2007 The North American Menopause Society. Unauthorized reproduction of this article is prohibited.
Furthermore, CGRP was found to support recruitment and
differentiation of periovarian brown adipocytes in cold
acclimated rats, suggesting its active involvement in AT
metabolism.35 The presence of CGRP in AT not only
supports the role of CGRP in maintaining body temperature,
because of its potent vasodilatory ability, but also provides a
possible mechanism by which AT may influence the severity
of hot flushes in postmenopausal women. Local adminis-
tration of CGRP-enhanced methacholine chloride induced
sweating in human volunteers, indicating that the occurrence
of sweats, after hot flushes, may be mediated through
CGRP.36 Visceral fat deposition is considered more patho-
genic than Sc AT and has been shown to increase the
relative risk of coronary heart diseaseYrelated deaths in
postmenopausal women.37 Visceral AT is metabolically
more active than Sc AT because it is able to mobilize free
fatty acids more readily.38 Therefore, paired samples of Sc
and Om AT were used in this study to investigate the
differential expression of CGRP and ADM in relation to fat
depot and to explore the mechanisms by which CGRP may
influence cardiovascular risk. We found a significantly
higher expression of RAMP1 in the Om fat tissue compared
with the Sc tissue, which indicates a possible mechanism by
which postmenopausal central adiposity may influence
CGRP activity. Previous studies by Wimalawansa39 suggest
that age may potentially influence CGRP expression in
certain tissues, although conflicting studies have shown no
such relationship.40,41 In the study by Schifter,40 232 healthy
individuals (109 male, 123 female) between 18 to 79 years
of age showed CGRP secretion to be unaffected by age.
Similarly, age was not found to affect the tissue contents of
CGRP in a study by Zaidi and colleagues.41
In a similar manner to CGRP, ADM also acts as a potent
vasodilator and plays an important role in maintaining
vascular homeostasis. AT has previously been reported to
express ADM mRNA.42,43 Our findings demonstrated that
ADM was highly expressed by human AT and adipocytes,
which is also influenced by menopause status. Overproduc-
tion of ADM has been found to be associated with the
existence of cardiovascular disease, and increased circula-
tory levels may have a prognostic value in some cardiovas-
cular diseases.20,21 Our studies indicate that higher
expression of ADM in AbSc AT, after menopause, may act
as a contributing source to cardiovascular risk associated
with menopause. Whether ADM is involved in vasodilata-
tion during hot flushes is, as yet, unknown, but intravenous
administration of ADM has been reported to cause skin
flushing, a phenomenon similar to CGRP.44 Although ADM
is mainly depicted as a circulatory peptide, local paracrine
effects in AT may represent an important site to maintain
normal microvasculature homeostasis. As such, increased
ADM mRNA expression in AT from postmenopausal
women indicates its possible involvement in the patho-
genesis of hot flushes along with CGRP.
It should be noted that in the study design, it was
important to ascertain BMI-matched pre- and postmeno-
pausal women to ensure that the effects we observed
between the two cohorts were due to menopause status and
not adiposity. As such, this has limited the ability to examine
the role of adiposity since the cohorts collected span a
narrow BMI range. Consequently no significant correlations
between >CGRP or ACGRP mRNA expression with BMI
were noted; subsequent studies should examine this in
further detail. In addition, because of our exclusion criteria,
this study was unable to examine patients who had
previously detailed severe vasomotor symptoms, such as
those patients on HT. These patients were excluded because
HT would influence AT metabolism and therefore may have
influenced CGRP expression. However, future studies
should explore the effects of estrogen directly on CGRP
expression in AT as well as the effects of increased BMI on
CGRP expression.
CONCLUSION
In conclusion, our studies demonstrated that AT may
represent an important site for the production and local
action of CGRP and ADM as important vasodilators. In
addition, the mRNA expression of ACGRP with RAMP2 and
RAMP3 positively correlated in human AT, suggesting the
possibility that ACGRP may act via the ADM receptors.
Taken together, these findings highlight the potential of AT
as a site of vasodilatory action, which our studies have
shown to be exacerbated by menopause status, with both
ADM and CGRP potentially contributing to menopausal hot
flashes as well as being associated with increased micro-
vascular disease associated with age.
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